Cargando…

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy

The combination of immunotherapy and molecular targeted therapy exhibits promising therapeutic efficacy in hepatocellular carcinoma (HCC), but the underlying mechanism is still unclear. Here, phosphoglycerate mutase 1 (PGAM1) is identified as a novel immunometabolic target by using a bioinformatic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Yimin, Wang, Yining, Lu, Zhou, Wan, Jinkai, Jiang, Lulu, Song, Danjun, Wei, Chuanyuan, Gao, Chao, Shi, Guoming, Zhou, Jian, Fan, Jia, Ke, Aiwu, Zhou, Lu, Cai, Jiabin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582428/ https://www.ncbi.nlm.nih.gov/pubmed/37705495 http://dx.doi.org/10.1002/advs.202301928

Ejemplares similares

The Design and Synthesis of N-Xanthone Benzenesulfonamides as Novel Phosphoglycerate Mutase 1 (PGAM1) Inhibitors
por: Wang, Penghui, et al.
Publicado: (2018)

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019)

Dysregulated ferroptosis‐related genes indicate potential clinical benefits for anti–PD‐1/PD‐L1 immunotherapy in lung adenocarcinoma
por: Zhou, Min, et al.
Publicado: (2021)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
por: Chen, Xi, et al.
Publicado: (2020)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Exosomal PGAM1 promotes prostate cancer angiogenesis and metastasis by interacting with ACTG1
por: Luo, Jun-qi, et al.
Publicado: (2023)

CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma
por: Guo, Xiao-Jun, et al.
Publicado: (2021)

Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer
por: Wang, Yue, et al.
Publicado: (2023)

Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy
por: Shi, Jiawei, et al.
Publicado: (2022)

The Loss of PGAM5 Suppresses the Mitochondrial Degeneration Caused by Inactivation of PINK1 in Drosophila
por: Imai, Yuzuru, et al.
Publicado: (2010)

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition
por: Han, Rui, et al.
Publicado: (2023)

S1P/S1PR3 axis promotes aerobic glycolysis by YAP/c-MYC/PGAM1 axis in osteosarcoma
por: Shen, Yifei, et al.
Publicado: (2018)

Intermittent dietary methionine deprivation facilitates tumoral ferroptosis and synergizes with checkpoint blockade
por: Xue, Ying, et al.
Publicado: (2023)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
por: Sun, Xuqi, et al.
Publicado: (2021)

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
por: Tian, Lingyu, et al.
Publicado: (2020)

PGAM1 regulation of ASS1 contributes to the progression of breast cancer through the cAMP/AMPK/CEBPB pathway
por: Liu, Min, et al.
Publicado: (2022)

Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation
por: Hitosugi, Taro, et al.
Publicado: (2013)

Construction of a prognostic model for HCC based on ferroptosis-related lncRNAs expression and its potential to predict the response and irAEs of immunotherapy
por: Dong, Liangbo, et al.
Publicado: (2023)

PGAM1 knockdown is associated with busulfan-induced hypospermatogenesis and spermatogenic cell apoptosis
por: Zhao, Yuanshu, et al.
Publicado: (2019)

Identification of PGAM1 as a putative therapeutic target for pancreatic ductal adenocarcinoma metastasis using quantitative proteomics
por: Liu, Xinlu, et al.
Publicado: (2018)

Ferroptosis in cancer and cancer immunotherapy
por: Zhao, Lei, et al.
Publicado: (2022)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

Targeted xCT‐mediated Ferroptosis and Protumoral Polarization of Macrophages Is Effective against HCC and Enhances the Efficacy of the Anti‐PD‐1/L1 Response
por: Tang, Bufu, et al.
Publicado: (2022)

Dihydroartemisinin Induces Ferroptosis in HCC by Promoting the Formation of PEBP1/15-LO
por: Su, Ying, et al.
Publicado: (2021)

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
por: Sun, Jin-Yu, et al.
Publicado: (2020)

Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma
por: Chai, Xiaoqiang, et al.
Publicado: (2022)

Efficacy and Safety of TKI Plus PD-1 Inhibitors in Elderly uHCC Patients: A Retrospective Study
por: Chen, Bowen, et al.
Publicado: (2022)

Bax-PGAM5L-Drp1 complex is required for intrinsic apoptosis execution
por: Xu, Wenjuan, et al.
Publicado: (2015)

Mitochondrial Protein PGAM5 Regulates Mitophagic Protection against Cell Necroptosis
por: Lu, Wei, et al.
Publicado: (2016)

Identification of human phosphoglycerate mutase 1 (PGAM1) inhibitors using hybrid virtual screening approaches
por: Yousaf, Numan, et al.
Publicado: (2023)

PGAM5 deacetylation mediated by SIRT2 facilitates lipid metabolism and liver cancer proliferation: PGAM5 deacetylation facilitates liver cancer proliferation
por: Fu, Gongyu, et al.
Publicado: (2023)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors
por: Matos, Ana I., et al.
Publicado: (2023)

The paradox of immunotherapy in NASH-HCC
por: Peng, Yao, et al.
Publicado: (2021)

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
por: Yi, Ming, et al.
Publicado: (2021)

Functional role of PGAM5 multimeric assemblies and their polymerization into filaments
por: Ruiz, Karen, et al.
Publicado: (2019)

Evaluation of nuclear PGAM2 value in hepatocellular carcinoma prognosis
por: Li, Yi-Ran, et al.
Publicado: (2021)

Dysregulation of the NUDT7-PGAM1 axis is responsible for chondrocyte death during osteoarthritis pathogenesis
por: Song, Jinsoo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_79155vsv6su7t4pnf3h0kg4dbd